Evidence map›Paper›PMID 35902728›Full record

ArticleCancer gene therapy2022

Epigenetically silenced apoptosis-associated tyrosine kinase (AATK) facilitates a decreased expression of Cyclin D1 and WEE1, phosphorylates TP53 and reduces cell proliferation in a kinase-dependent manner.

Michelle L Woods, Astrid Weiss, Anna M Sokol, Johannes Graumann, Thomas Boettger, Antje M Richter, Ralph T Schermuly, Reinhard H Dammann

Open access · hybridAbstract read
In one paragraph

Article in Cancer gene therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Michelle L WoodsInstitute for Genetics, Justus-Liebig-University Giessen, 35392, Giessen, Germany.
Astrid WeissDepartment of Internal Medicine, Justus-Liebig-University Giessen, 35392, Giessen, Germany.ORCID 0000-0002-1788-2666
Anna M SokolScientific Service Group Biomolecular Mass Spectrometry, Max-Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany.
Johannes GraumannScientific Service Group Biomolecular Mass Spectrometry, Max-Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany.ORCID 0000-0002-3015-5850
Thomas BoettgerMax-Planck Institute for Heart and Lung Research, 61231, Bad Nauheim, Germany.ORCID 0000-0003-4280-8449
Antje M RichterInstitute for Genetics, Justus-Liebig-University Giessen, 35392, Giessen, Germany.ORCID 0000-0002-9392-1495
Ralph T SchermulyDepartment of Internal Medicine, Justus-Liebig-University Giessen, 35392, Giessen, Germany.ORCID 0000-0002-5167-6970
Reinhard H DammannInstitute for Genetics, Justus-Liebig-University Giessen, 35392, Giessen, Germany. reinhard.dammann@gen.bio.uni-giessen.de.ORCID 0000-0001-6407-1236
Justus-Liebig-Universität Gießen · DEMax Planck Institute for Heart and Lung Research · DEPhilipps University of Marburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Silencing of the Apoptosis associated Tyrosine Kinase gene (AATK) has been described in cancer. In our study, we specifically investigated the epigenetic inactivation of AATK in pancreatic adenocarcinoma, lower grade glioma, lung, breast, head, and neck cancer. The resulting loss of AATK correlates with impaired patient survival. Inhibition of DNA methyltransferases (DNMTs) reactivated AATK in glioblastoma and pancreatic cancer. In contrast, epigenetic targeting via the CRISPR/dCas9 system with either EZH2 or DNMT3A inhibited the expression of AATK. Via large-scale kinomic profiling and kinase assays, we demonstrate that AATK acts a Ser/Thr kinase that phosphorylates TP53 at Ser366. Furthermore, whole transcriptome analyses and mass spectrometry associate AATK expression with the GO term 'regulation of cell proliferation'. The kinase activity of AATK in comparison to the kinase-dead mutant mediates a decreased expression of the key cell cycle regulators Cyclin D1 and WEE1. Moreover, growth suppression through AATK relies on its kinase activity. In conclusion, the Ser/Thr kinase AATK represses growth and phosphorylates TP53. Furthermore, expression of AATK was correlated with a better patient survival for different cancer entities. This data suggests that AATK acts as an epigenetically inactivated tumor suppressor gene.

Indexed as

AdenocarcinomaApoptosis Regulatory ProteinsPancreatic NeoplasmsProtein-Tyrosine KinasesCell Cycle ProteinsCell Line, TumorCell ProliferationCyclin D1HumansTumor Suppressor Protein p53AATK protein, humanApoptosis Regulatory ProteinsCell Cycle ProteinsCyclin D1Protein-Tyrosine KinasesTP53 protein, humanTumor Suppressor Protein p53WEE1 protein, human

Identifiers

PMID35902728
PMCPMC9750878
OpenAlexW4288080510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.